Isara

TOPPAN Holdings NICT and ISARA Establish Proof of Concept for Post-Quantum Cryptography Migration

TOPPAN Holdings NICT and ISARA completed a proof of concept on April 9 2026 for seamless migration technology to Post-Quantum Cryptography for certificate authorities. The secondary root certificate approach maintains security during phased transition from current cryptography to PQC in internet communications infrastructure. TOPPAN Holdings NICT and ISARA validated the method for certificate authority frameworks supporting both legacy and quantum-safe systems.

ISARA and Carahsoft Partner to Accelerate Quantum Readiness for US Government

ISARA Corporation partnered with Carahsoft Technology Corp on January 22 2026 to distribute quantum readiness solutions to US federal agencies. The agreement makes ISARA’s cryptographic posture management and Post-Quantum Cryptography tools available through Carahsoft resellers and contracts including SEWP V ITES-SW2 TIPS NASPO OMNIA and E&I. Federal agencies gain access to cryptographic inventory assessments PQC implementations and crypto-agility solutions for zero trust and compliance with mandates like OMB Memorandum 23-02.

ISARA Corporation seeks Demand Generation Manager amid first-mover quantum-safe cryptography push

OpenAI invests in Isara, a $650M startup building AI agent swarms

Isara raised $94 million at a $650 million valuation with OpenAI as an investor on March 27, 2026. The nine-month-old San Francisco company, founded in June 2025 by two 23-year-olds Eddie Zhang and Henry Gasztowtt, develops multi-agent coordination software allowing hundreds or thousands of specialized AI agents to communicate, divide tasks, and align on goals for complex analytical tasks such as approximately 2,000 agents forecasting the price of gold. Primary target market is investment firms with secondary markets in biotechnology and geopolitical analysis. Isara has hired approximately twelve researchers from Google, Meta, and OpenAI. OpenAI’s involvement forms part of the broader pattern of $2.5 billion invested across five neolab research-heavy AI startups.

OpenAI backs new AI startup Isara seeking bot army breakthroughs

OpenAI is backing a new AI startup Isara which aims to build software allowing AI agents to communicate and solve complex problems

OpenAI backed Isara in a $94 million funding round at a $650 million valuation announced in March 2026. Isara, founded in June 2025 by Eddie Zhang and Henry Gasztowtt, creates software for AI agents to collaborate on complex problems in finance and biotech. Investors include Amity Ventures, Michael Ovitz, and Stanley Druckenmiller. The startup has three employees and focuses on predictive modeling tools.

Isara $94M Series A Funding (2026) | Investors & Contacts

Isara completed a $94 million Series A funding round in 2026 at a $650 million valuation. OpenAI participated alongside Amity Ventures, Michael Ovitz, and Stanley Druckenmiller. The company, founded in 2025 by Eddie Zhang and Henry Gasztowtt, develops AI agent swarm technology for predictive modeling. Isara targets finance firms as initial customers for its tools.

Isara raises $94M Series A at $650M valuation with OpenAI investment

Isara, a San Francisco AI startup founded in June 2025 by Eddie Zhang and Henry Gasztowtt, raised $94 million in a Series A round at a $650 million valuation. OpenAI joined investors Amity Ventures, Michael Ovitz, and Stanley Druckenmiller in the round. The company builds software for multi-agent AI systems that coordinate thousands of agents on tasks like predictive modeling in finance and biotech. Isara has three employees and targets investment firms for its first predictive tools.

Google-Backed Isomorphic Labs Raises $2.1 Billion for AI-Driven Drug Efforts

Isomorphic Labs raised $2.1 billion in funding on May 12, 2026, led by Thrive Capital. The round includes Google Ventures, Alphabet, MGX, Temasek, and CapitalG as participants. Proceeds fund expansion of AI models for drug discovery across modalities and partnerships. Agreements with Novartis, Eli Lilly, and Johnson & Johnson incorporate IsoDDE into joint programs with milestone structures. Demis Hassabis founded the company in 2021, building on DeepMind technology for a London base.

Isomorphic Labs' $2.1 Billion Raise Highlights AI Drug Discovery Momentum

Isomorphic Labs announced a $2.1 billion Series B funding round on May 13, 2026, led by Thrive Capital. Investors include Alphabet, GV, MGX from Abu Dhabi, Temasek from Singapore, CapitalG, and the UK Sovereign AI Fund. The capital accelerates IsoDDE engine scaling for therapeutic applications and global operations growth. Existing deals with Novartis, Eli Lilly, and Johnson & Johnson provide $600 million in near-term milestones based on development benchmarks. The firm, founded by Demis Hassabis in 2021, has raised $2.7 billion total without corporate venture involvement in this round.

Isomorphic Labs Announces $2.1 Billion Series B to Advance AI Drug Pipeline

Isomorphic Labs secured $2.1 billion in Series B funding on May 12, 2026, led by Thrive Capital. The round features Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund as investors. Funds will enhance the IsoDDE AI model for drug discovery and support internal candidate progression. Collaborations with Novartis, Eli Lilly, and Johnson & Johnson integrate IsoDDE into their R&D pipelines with defined milestones. Max Jaderberg serves as president under founder Demis Hassabis at the London headquarters established in 2021.

Alphabet's Isomorphic Labs Secures $2.1 Billion Series B for AI Drug Design Expansion

Isomorphic Labs completed a $2.1 billion Series B funding round on May 12, 2026, led by Thrive Capital. Existing investors Alphabet and GV joined alongside new participants MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. The investment follows a $600 million round in 2025 and supports development of the IsoDDE engine for multi-modal drug design across therapeutic areas. Partnerships with Novartis, Eli Lilly, and Johnson & Johnson include milestone payments totaling $600 million tied to clinical progress. Demis Hassabis leads the London-based firm, which originated from DeepMind's AlphaFold project in 2021.

Isomorphic Labs Raises $2.1 Billion in Series B Funding Led by Thrive Capital

Isomorphic Labs raised $2.1 billion in Series B funding on May 12, 2026. Thrive Capital led the round with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. The company will use the funds to scale its IsoDDE AI drug design engine, expand globally, and advance its internal drug pipeline. Isomorphic Labs maintains partnerships with Novartis, Eli Lilly, and Johnson & Johnson for AI-driven drug discovery programs. Total funding now reaches $2.7 billion since its 2021 founding by Demis Hassabis.

Isara's CEO steps down amid internal restructuring. Sources say it's to focus on advisory roles, but whispers of perform

Isara's CEO steps down amid internal restructuring. Sources say it's to focus on advisory roles, but whispers of performance issues. Leadership change could impact their market position. #TechNews

Partnership alert: Isara teams up with IBM for post-quantum encryption standards. #Partnerships #Quantum

Isara announces $10M seed funding for quantum-safe cryptography solutions. Timely amid rising threats. #Funding #Cyberse

Isara announces $10M seed funding for quantum-safe cryptography solutions. Timely amid rising threats. #Funding #Cybersecurity